Johns Hopkins University School of Medicine, 1830 E Monument Street, Baltimore, MD 21287, USA.
Johns Hopkins University School of Medicine, 733 North Broadway, Baltimore, MD 21205, USA.
Med Clin North Am. 2022 Mar;106(2):285-298. doi: 10.1016/j.mcna.2021.11.005. Epub 2022 Feb 2.
One's total atherosclerotic plaque burden is related to his or her cumulative exposure to low-density lipoprotein cholesterol (LDL-C) and other apoB-containing lipoproteins. Long-term exposure to lower LDL-C levels is associated with a lower risk of cardiovascular events compared with shorter term exposure to lower LDL-C. New lipid-reducing agents have been able to reduce LDL-C to previously unseen levels, showing efficacy in safely decreasing rates of atherosclerotic cardiovascular disease in primary and secondary prevention populations. To date, an LDL-C level less than which there is no clinical benefit has not yet been identified.
一个人的总动脉粥样硬化斑块负担与他或她接触到的低密度脂蛋白胆固醇（LDL-C）和其他载脂蛋白 B 脂蛋白的累积量有关。与短期接触较低 LDL-C 相比，长期接触较低 LDL-C 与心血管事件风险降低相关。新型降脂药物已能将 LDL-C 降低到前所未有的水平，在一级和二级预防人群中安全降低动脉粥样硬化性心血管疾病的发生率方面显示出疗效。迄今为止，尚未确定 LDL-C 水平低于该水平时没有临床获益。
